argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -425.04 Million USD | 40.94% |
| 2022 | -719.66 Million USD | -106.36% |
| 2021 | -348.74 Million USD | 32.13% |
| 2020 | -513.83 Million EUR | -156.9% |
| 2019 | -200.01 Million EUR | -113.62% |
| 2018 | -93.62 Million EUR | -240.32% |
| 2017 | -27.51 Million EUR | -22.15% |
| 2016 | -22.52 Million EUR | -32.02% |
| 2015 | -17.06 Million EUR | -30.6% |
| 2014 | -13.06 Million EUR | -51.85% |
| 2013 | -8.6 Million EUR | 35.28% |
| 2012 | -13.29 Million EUR | -181.75% |
| 2011 | -4.71 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -158.62 Million USD | -69.8% |
| 2024 Q1 | -93.42 Million USD | 36.9% |
| 2023 Q1 | -103.74 Million USD | 8.8% |
| 2023 Q2 | -102.09 Million USD | 1.59% |
| 2023 FY | -425.04 Million USD | 40.94% |
| 2023 Q4 | -148.05 Million USD | -83.72% |
| 2023 Q3 | -80.58 Million USD | 21.06% |
| 2022 Q4 | -113.75 Million USD | 45.48% |
| 2022 Q2 | -174.54 Million USD | 21.63% |
| 2022 Q1 | -222.72 Million USD | 3.55% |
| 2022 Q3 | -208.63 Million USD | -19.53% |
| 2022 FY | -719.66 Million USD | -106.36% |
| 2021 FY | -348.74 Million USD | 32.13% |
| 2021 Q1 | -13 Thousand EUR | -100.01% |
| 2021 Q2 | 95.13 Million USD | 731915.38% |
| 2021 Q3 | -212.95 Million USD | -323.84% |
| 2021 Q4 | -230.91 Million USD | -8.43% |
| 2020 Q4 | 258.02 Million USD | 353.38% |
| 2020 Q3 | -101.83 Million EUR | 0.0% |
| 2020 FY | -513.83 Million EUR | -156.9% |
| 2019 FY | -200.01 Million EUR | -113.62% |
| 2019 Q1 | -6.78 Million EUR | 82.47% |
| 2019 Q2 | -55.14 Million EUR | -712.86% |
| 2019 Q3 | -48.88 Million EUR | 11.34% |
| 2019 Q4 | -75.19 Million EUR | -53.81% |
| 2018 Q4 | -38.69 Million EUR | -51.23% |
| 2018 Q2 | -11.91 Million EUR | 31.7% |
| 2018 Q1 | -17.44 Million EUR | -49.3% |
| 2018 FY | -93.62 Million EUR | -240.32% |
| 2018 Q3 | -25.58 Million EUR | -114.78% |
| 2017 Q1 | -8.97 Million EUR | -6.57% |
| 2017 FY | -27.51 Million EUR | -22.15% |
| 2017 Q4 | -11.68 Million EUR | -44.13% |
| 2017 Q3 | -8.1 Million EUR | -749.93% |
| 2017 Q2 | 1.24 Million EUR | 113.9% |
| 2016 Q4 | -8.41 Million EUR | -42.08% |
| 2016 FY | -22.52 Million EUR | -32.02% |
| 2016 Q3 | -5.92 Million EUR | -23.23% |
| 2016 Q2 | -4.8 Million EUR | -42.66% |
| 2016 Q1 | -3.37 Million EUR | 39.09% |
| 2015 FY | -17.06 Million EUR | -30.6% |
| 2015 Q4 | -5.53 Million EUR | -62.93% |
| 2015 Q3 | -3.39 Million EUR | 26.71% |
| 2015 Q2 | -4.63 Million EUR | -32.48% |
| 2015 Q1 | -3.49 Million EUR | 25.08% |
| 2014 FY | -13.06 Million EUR | -51.85% |
| 2014 Q4 | -4.66 Million EUR | -127.61% |
| 2014 Q2 | -3.73 Million EUR | -43.16% |
| 2014 Q1 | -2.6 Million EUR | -23.68% |
| 2014 Q3 | -2.05 Million EUR | 45.08% |
| 2013 Q3 | -97.6 Thousand EUR | 97.56% |
| 2013 Q2 | -4 Million EUR | -67.07% |
| 2013 Q4 | -2.1 Million EUR | -2061.35% |
| 2013 FY | -8.6 Million EUR | 35.28% |
| 2013 Q1 | -2.39 Million EUR | 0.0% |
| 2012 FY | -13.29 Million EUR | -181.75% |
| 2011 FY | -4.71 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | -2281.627% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -109007.221% |
| Nascent Biotech, Inc. | -2.22 Million USD | -18961.528% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -102203.366% |
| Qrons Inc. | -643.67 Thousand USD | -65934.517% |
| Rebus Holdings, Inc. | -664 Thousand USD | -63913.404% |
| Skye Bioscience, Inc. | -13.67 Million USD | -3008.947% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 619.29% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | -665.744% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -2578.362% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -8326.017% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -31728.601% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | -492.106% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 8748.328% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -162302.283% |
| SQZ Biotechnologies Company | -75.82 Million USD | -460.566% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -14811.347% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -27571.578% |
| Mesoblast Limited | -84.14 Million USD | -405.127% |
| Marizyme, Inc. | -34.08 Million USD | -1146.971% |
| Genus plc | 6.4 Million USD | 6741.391% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 4462.851% |
| Pharming Group N.V. | -4.87 Million USD | -8610.834% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -21297.105% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -45536.475% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -4990.407% |
| ContraFect Corporation | -56.88 Million USD | -647.155% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -9232.043% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -30217.527% |
| IMV Inc. | -38.67 Million USD | -999.127% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -15351.613% |
| MultiCell Technologies, Inc. | -722.81 USD | -58804980.173% |
| ONE Bio Corp. | 13.68 Million USD | 3206.732% |
| Accustem Sciences Inc. | -3.74 Million USD | -11245.474% |
| RVL Pharmaceuticals plc | -58.99 Million USD | -620.544% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -87890.568% |
| Q BioMed Inc. | -3.44 Million USD | -12235.936% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 12107.034% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -16076.801% |
| Biomind Labs Inc. | -1 Million USD | -42000.608% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | -673.205% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -14550.547% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -6293.623% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -22698.532% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -1419000.561% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -21893.522% |
| GB Sciences, Inc. | -1.42 Million USD | -29822.302% |
| Alpha Cognition Inc. | -9.7 Million USD | -4279.42% |
| HST Global, Inc. | -140.9 Thousand USD | -301552.154% |
| CSL Limited | 3.7 Billion USD | 111.482% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -37685.291% |
| Halberd Corporation | -75.05 Thousand USD | -566254.43% |
| Enzolytics Inc. | -2.14 Million USD | -19680.761% |
| Agentix Corp. | -1.37 Million USD | -30885.758% |
| Resverlogix Corp. | -12.74 Million USD | -3233.979% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -13315.79% |
| MetaStat, Inc. | - USD | Infinity% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -40613.506% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -14459.245% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -26812.822% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -12383.161% |
| AVAX Technologies, Inc. | 6.69 Million USD | 6450.764% |
| Zenith Capital Corp. | -8.94 Million USD | -4652.868% |
| Genscript Biotech Corporation | -415.79 Million USD | -2.227% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -2439765.679% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -17211.37% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -247728.197% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -21102.021% |
| Kadimastem Ltd | -3.04 Million USD | -13880.725% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -43093.71% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -33741.481% |
| BioStem Technologies, Inc. | -7.77 Million USD | -5364.079% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -234106.133% |
| LadRx Corporation | -3.82 Million USD | -11016.385% |
| Cell Source, Inc. | -4.32 Million USD | -9726.936% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -61774.809% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -61774.809% |
| NovAccess Global Inc. | -2.46 Million USD | -17131.064% |
| Affymax, Inc. | -15.04 Million USD | -2724.997% |
| Itoco Inc. | -919.14 Thousand USD | -46144.207% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -9928.492% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -37884.718% |
| Mobile Lads Corp. | -554.55 Thousand USD | -76547.552% |
| CytoDyn Inc. | -18.05 Million USD | -2253.799% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -1688612.753% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -193035.616% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -75166.812% |
| SYBLEU INC | -149.18 Thousand USD | -284823.582% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -23301.658% |
| International Stem Cell Corporation | -663 Thousand USD | -64009.955% |
| Bioxytran, Inc. | -3.82 Million USD | -11026.509% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -807363.906% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -2089619.764% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | -1072.032% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -26170.025% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -57664.173% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -13562.777% |
| Neutra Corp. | -229.48 Thousand USD | -185117.835% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -2323.451% |
| PureTech Health plc | -146.19 Million USD | -190.733% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -1877.789% |
| IXICO plc | -1.43 Million USD | -29478.914% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -4378.443% |
| Gelesis Holdings, Inc. | -121.8 Million USD | -248.956% |
| CSL Limited | 3.81 Billion USD | 111.15% |
| Cellectis S.A. | -108.85 Million USD | -290.464% |